Search Bar & Filters
Found 63 Actively Recruiting clinical trials
Actively Recruiting
Women who have experienced interpersonal violence often face a higher risk of developing post-traumatic stress disorder PTSD. In France, female victims can request a medico-legal examination at a clinical forensic medicine unit, which also offers initial psychological assessment. However, many women do not attend follow-up appointments. This research is a prospective, multicenter, open-label, randomized controlled trial aiming to evaluate the effectiveness of a case management algorithm that uses early phone contact to improve clinical outcomes after such consultations for female victims of violence. Participants are divided into two groups. The experimental group, called VIGITRAUMA, will receive a phone call three weeks after their consultation, with a second call if needed. If contact is not made after the second call, a postcard will be sent. The control group will receive the usual follow-up care without this additional phone contact. The study is conducted by the University Hospital, Lille. Participants will be assessed through phone calls at 3, 6, and 12 months after their consultation to monitor clinical outcomes. Researchers will measure PTSD symptom severity, general psychopathology, somatic symptoms, medical costs, judicial outcomes, suicidal thoughts, and suicide attempts. The study aims to track these outcomes over a full year to understand the impact of the case management algorithm compared to standard care.
Actively Recruiting
Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.
Actively Recruiting
Researchers are studying cryoglobulinemic vasculitis CV, a rare and serious immune system disorder that causes inflammation of blood vessels and can affect the skin, joints, kidneys, nerves, and other organs. This trial focuses on patients with active non-infectious CV who have not responded well to or cannot tolerate the current standard treatment Rituximab. The study aims to evaluate the safety and effectiveness of a different antibody treatment called Obinutuzumab in these patients. Participants will receive Obinutuzumab through an intravenous infusion at a dose of 1000 milligrams given at the start of the study and again two weeks later. This treatment is being assessed as a potential new option for CV patients who have limited choices due to resistance or intolerance to Rituximab. The trial is conducted as a single-arm study, meaning all participants receive Obinutuzumab, and it is designed as a phase 2 proof-of-concept study. During the study, participants will be monitored regularly for clinical response, side effects, and changes in disease activity using various clinical and laboratory tests over several months. Key outcomes include the rate of complete clinical response at 6 months, safety events up to 48 weeks, and longer-term measures of disease relapse and survival up to almost three years. Participants will undergo assessments including physical exams, laboratory tests, and disease activity scores to track progress and safety throughout the trial.
Actively Recruiting
Malignant hypertension is a very serious form of high blood pressure that can be fatal if untreated. This research aims to create the first large, multicenter database to better understand this disease, including its modern epidemiology, how patients are currently managed, and the diseases diagnostic criteria. The study will help improve knowledge and may lead to new treatment trials and evidence-based recommendations. The study is an observational registry enrolling patients diagnosed with malignant hypertension based on classic definitions, including severe blood pressure elevation and organ damage. It plans to recruit 500 patients and follow them for five years to study their prognosis and the impact of different patient characteristics and organ involvement. By collecting detailed data on disease features and care pathways, the study hopes to update definitions and management approaches. Participants will be observed over five years, with researchers collecting information on their health status, organ damage, and treatment. The main outcome measured is the five-year prognosis of patients. This long-term follow-up will provide detailed knowledge about the disease course and help identify factors influencing outcomes, without any study treatments or interventions being assigned.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.
Actively Recruiting
Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.
Actively Recruiting
Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
1-10 of 63
1